Several active research areas include: Metabolic dysfunction-associated steatotic liver disease (MASLD) : Multiple trials are evaluating semaglutide's effects on liver fat content and biomarkers, with preliminary data suggesting potential benefits in reducing hepatic steatosis and improving liver enzyme profiles Chronic kidney disease : Studies examining renal outcomes in patients with type 2 diabetes and established kidney disease, building on secondary analyses from SUSTAIN 6 showing reduced progression of diabetic nephropathy Obstructive sleep apnea : Ongoing trials investigating whether weight loss achieved with semaglutide improves sleep apnea severity and related cardiovascular outcomes Addiction and substance use disorders : Early-phase research exploring GLP-1 receptor agonists' potential effects on reward pathways and addictive behaviors, though this remains highly preliminary Alzheimer's disease and cognitive function : Preclinical evidence suggesting neuroprotective properties has prompted clinical trials examining cognitive outcomes in at-risk populations Researchers are also investigating combination therapies , such as cagrilintide plus semaglutide (CagriSema), which is currently under development
Registration number AM.01.07.01.003.R.000945.07.24 of 01.07.2024 Release form 60 capsules, 0.2 g Keep out of reach of children, at a temperature not exceeding 25 C Shelf life: 3 years Manufacturer/organization accepting claims: CJSC Evalar, Russia, Altai Territory, 659332, Biysk, Socialisticheskaya Str., 23/6, www.evalar.ru
The Section of Endocrinology at Imperial College London is funded by grants from the MRC, NIHR and is supported by the NIHR Biomedical Research Centre Funding Scheme and the NIHR/Imperial Clinical Research Facility
#NovoNordisk #Ozempic #Semaglutide #GLP1 #Type2Diabetes #Obesity #AccessToMedicine #HealthcareInnovation #Pharma #EmergingMarkets Novo Nordisks launch of Extensior in South Africa is a smart, strategically timed move that tackles two challenges at once: affordability barriers and the rapid rise of greymarket semaglutide
Perspect Biol Med 1996
